Clinical Trials on Lymphoma, Follicular

Total 9599 results

University of Washington
AstraZeneca

Recruiting

Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma

B-Cell Non-Hodgkin Lymphoma | Primary Mediastinal (Thymic) Large B-Cell Lymphoma | High Grade B-Cell Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Transformed Follicular Lymphoma to Diffuse...

United States
Pell Bio-Med Technology Co., Ltd.

Recruiting

Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy

Diffuse Large B Cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Large B-cell Lymphoma | Follicular Lymphoma Grade 3B | Follicular Lymphoma Grade 3A

Taiwan
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma

Follicular Lymphoma

United States
Weill Medical College of Cornell University
Epizyme, Inc.; Genentech, Inc.

Recruiting

Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma

Follicular Lymphoma

United States
Fondazione Italiana Linfomi - ETS

Recruiting

Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial (FIL_FOLL-BIO)

Follicular Lymphoma

Italy
Memorial Sloan Kettering Cancer Center

Recruiting

A Study of Mosunetuzumab in People With Follicular Lymphoma

Lymphoma | Follicular Lymphoma

United States
Ruijin Hospital

Recruiting

Rituximab Maintenance Treatment of Newly Diagnosed Follicular Lymphoma After BR or RCHOP or R2: a Multicenter Clinical Study

Follicular Lymphoma

China
National Cancer Institute (NCI)

Recruiting

Clonal Evolution in Follicular Lymphoma

Follicular Lymphoma

United States
XEME Biopharma Inc.

Not yet recruiting

Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular Lymphoma

Follicular Lymphoma

United States
Hoffmann-La Roche

Active, not recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma

Follicular Lymphoma

United Kingdom, United States, China, France, Spain
Epizyme, Inc.
Swedish Cancer Institute

Terminated

SYMPHONY-2, A Trial to Examine Combination of Tazemetostat With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma

Follicular Lymphoma

United States
Novartis Pharmaceuticals

Active, not recruiting

Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma (ELARA)

Follicular Lymphoma

United States, Spain, Belgium, Japan, Australia, Germany, Italy, Netherlands, Norway, United Kingdom, Austria, France
Dana-Farber Cancer Institute

Active, not recruiting

Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma

Follicular Lymphoma

United States
Innovent Biologics (Suzhou) Co. Ltd.

Withdrawn

Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma

Follicular Lymphoma

China
Washington University School of Medicine

Terminated

Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma

Follicular Lymphoma

United States
Gilead Sciences

Terminated

Dose Optimization Study of Idelalisib in Follicular Lymphoma

Follicular Lymphoma

Spain, Italy, France, Poland, Israel, United Kingdom, Czechia, Romania, Australia, Canada
The Lymphoma Academic Research Organisation
Roche Pharma AG

Completed

Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT) (FLIRT)

Follicular Lymphoma

France
Columbia University
TG Therapeutics, Inc.

Terminated

TGR1202 in Relapsed and Refractory Follicular Lymphoma

Follicular Lymphoma

United States
Celltrion

Completed

To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma

Follicular Lymphoma

Korea, Republic of
M.D. Anderson Cancer Center
Cephalon

Terminated

Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma

Follicular Lymphoma

United States
Cho Pharma Inc.

Unknown

A Phase I Study of Intravenous CHO-H01 in Patients With Refractory or Relapsed Follicular Lymphoma

Follicular Lymphoma
Lymphoma Study Association
Institute of Cancer Research, United Kingdom; Australasian Leukaemia and Lymphoma... and other collaborators

Completed

Primary Rituximab and Maintenance

Follicular Lymphoma

France, Thailand, Belgium, Spain, Argentina, Australia, Brazil, Colombia, Denmark, Netherlands, New Zealand, Peru
Hospices Civils de Lyon

Completed

CD180 Overexpression in Follicular Lymphoma

Follicular Lymphoma
Hoffmann-La Roche

Completed

Rituximab Therapy in Follicular Lymphoma in Combination With Chemotherapy - REFLECT 1

Follicular Lymphoma

Serbia
Memorial Sloan Kettering Cancer Center
Celgene Corporation

Withdrawn

Lenalidomide Therapy In Previously Untreated, Advanced Stage Follicular Lymphoma

Lymphoma | Follicular Lymphoma
IRCCS Policlinico S. Matteo

Completed

Immunochemotherapy, in Vivo Purging, PBSC Mobilization and Autotransplant in Relapsed or Refractory Follicular Lymphoma

Follicular Lymphoma

Italy
Oslo University Hospital
University of Oslo

Unknown

Dietary Intervention in Follicular Lymphoma (KLYMF)

Follicular Lymphoma

Norway
Azienda Ospedaliera San Giovanni Battista
Hoffmann-La Roche; University of Turin, Italy; Gruppo Italiano Trapianto di Midollo... and other collaborators

Unknown

Comparison of High-Dose Chemotherapy + Rituximab and CHOP + Rituximab in High-Risk Follicular Lymphoma

Follicular Lymphoma

Italy
Gruppo Italiano Studio Linfomi

Completed

Safety and Efficacy of Fludarabine and Cyclophosphamide + Rituximab

Follicular Lymphoma

Italy
National Cancer Institute (NCI)

Completed

Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Splenic Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma

United States
National Cancer Institute (NCI)

Terminated

Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Adult Non-Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Lymphoproliferative Disorders

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma

United States
AbbVie
Genmab

Recruiting

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1)

Follicular Lymphoma (FL)

Austria, Greece, Israel, Korea, Republic of, Spain, Hungary, Sweden, Switzerland, France, Poland, Taiwan, Australia, Denmark, New Zealand, Turkey, Italy, Netherlands, Belgium, Canada, South Africa, Czechia, Brazil, Germany, Argentina, United... and more
Fondazione Italiana Linfomi - ETS

Active, not recruiting

A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)

Relapsed Follicular Lymphoma

Italy
SecuraBio

Terminated

A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)

CD20+ Follicular Lymphoma

Belgium, Italy, United States, Spain, United Kingdom, France
Lymphoma Study Association
Janssen-Cilag International NV

Terminated

A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma

Follicular Lymphoma

France, Belgium
Weill Medical College of Cornell University
Memorial Sloan Kettering Cancer Center

Terminated

A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma

United States
Tel-Aviv Sourasky Medical Center

Unknown

Non-invasive Evaluation of Lymphoma Patients Based on Artificial Intelligence and PET/MRI

Lymphoma | Follicular Lymphoma | Non Hodgkin Lymphoma
Robert Lowsky
National Cancer Institute (NCI)

Completed

A Phase I/II Study of Intratumoral Injection of SD-101

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone Lymphoma | Recurrent Small Lymphocytic...

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma

Ann Arbor Stage I Grade 1 Follicular Lymphoma | Ann Arbor Stage I Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 1 Follicular Lymphoma | Ann Arbor Stage II Grade 2 Follicular Lymphoma | Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma | Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma | Ann... and other conditions

United States
AbbVie
Genmab

Recruiting

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCORE™FL-2)

Follicular Lymphoma (FL)

United States, Puerto Rico
M.D. Anderson Cancer Center
Bristol-Myers Squibb

Not yet recruiting

Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma

Follicular Lymphoma | Tumor

United States
Regeneron Pharmaceuticals

Recruiting

A Study to Learn How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Compared to Rituximab and Chemotherapy in Adult Participants With Previously Untreated Follicular Lymphoma (OLYMPIA-2)

Follicular Lymphoma (FL)

Spain, United States, Turkey, Thailand, Belgium, Poland, Chile, Italy
Regeneron Pharmaceuticals

Recruiting

A Trial to Learn if Odronextamab is Safe and Well-tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma (OLYMPIA-1)

Follicular Lymphoma (FL)

Taiwan, Spain, Israel, Poland, United States, Austria, Turkey, Czechia, Australia, Italy, United Kingdom, Chile
Novartis Pharmaceuticals

Recruiting

A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma (LEDA)

Follicular Lymphoma (FL)

Australia, Korea, Republic of, Spain, Singapore, Poland, Taiwan, Hungary, Romania, Slovakia
Millennium Pharmaceuticals, Inc.

Completed

Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma

Relapsed Follicular Lymphoma

United States, Puerto Rico
Regeneron Pharmaceuticals

Completed

Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed or Refractory Follicular Lymphoma (FLORA)

Relapsed/Refractory Follicular Lymphoma

Austria, France, Germany, United Kingdom
Gilead Sciences

Terminated

Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Non-hodgkin's Lymphoma | Small Lymphocytic Lymphoma

United States
Novartis Pharmaceuticals

Completed

Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL

Follicular Lymphoma, Mantle Cell Lymphoma

Austria, France, United States, Germany
National Cancer Institute (NCI)

Completed

Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines

Lymphoma | Follicular Lymphoma | B Cell Lymphoma

United States

Clinical Trials on Lymphoma, Follicular

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations